About Anat Stemmer-Rachamimov, MD

Anat Stemmer-Rachamimov, MD, is a faculty member of the C. S. Kubik Laboratory for Neuropathology providing diagnostic services, instruction to trainees on the Neuropathology service through didactic teaching sessions and routine sign-out procedures. She is the co-director of the DFHCC Specialized Histopathology Services Core, co-director of the Neuro Oncology Tissue Repository and the director of the Automated Biomarker Laboratory.

Her conference activities include weekly or monthly conferences with Pathology, Neurology and Neuro-Oncology. She has particular interest in tumor pathology and the weekly consensus review sessions in which all primary brain tumors are discussed, along with cases of complexity or particular interest. This session allows the neuropathology staff to maintain a consistent set of diagnostic criteria and terminology.

She is one of four neuropathologists that diagnose approximately 700 in-house surgical neuropathology cases, and 500 consultation cases per year. In a given year, over 900 intra-operative diagnostic consultations are processed.
Her research interests focus on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes in particular, neurofibromatosis 1, neurofibromatosis 2, schwannomatosis, and tuberous sclerosis; and comparative pathology with genetically modified mouse models.

Departments, Centers, & Programs:

Clinical Interests:




Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800

Medical Education

  • MD, University of Milan
  • Residency, Memorial Hospital Health Science Centre, St. John's
  • Residency, University Hospital Health Science Center Canada
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Anatomic Pathology, American Board of Pathology
  • Neuropathology, American Board of Pathology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Our lab's research focuses on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes (neurofibromatosis 1, neurofibromatosis 2, schwannomatosis and tuberous sclerosis), and the identification of activated pathways or events that lead to tumor progression. We are now moving from defining the molecular features and understanding the biology to more practical translational research of biomarkers and drug screens.

See details at the Stemmer-Rachamimov Lab.


Reviews: Comments and Ratings